Prabha Raghavan

Articles By Prabha Raghavan

Despite MSME objections, govt moves plan to curb special steel imports

Representations show that manufacturers like Tata-owned Tinplate Company of India (TCIL), O P Jindal group’s JSW Vallabh Tinplate Pvt (VTPL) and Parikh Group of Companies’s GPT Steel Industries (GPT) together have a capacity of 660,000 tonnes.

‘Expedite solution to cases of overcharging for essential medicines’

The departments are expected to work out other viable options of resolving this issue as well and come back with a proposal “at the earliest”, a senior government official said on condition of anonymity.

Top drug advisory board clears move to ban vapes and e-cigarettes

Once notified by the Health Ministry, the CDSCO will be able to prohibit the manufacture, sale and distribution of these Electronic Nicotinic Delivery Systems

One-hit wonders: Smaller pharma companies with blockbuster brands

In India’s diverse pharma industry, it’s not about how big the firm is, but how popular they can make their brands. This has allowed lesser-known drug makers to build brands that are to be reckoned with

In a ‘first’, Gujarat to launch trading system with incentive for low polluting industries

The programme is being piloted in Surat as it is a densely populated industrial centre where textile and dye mills release a “significant” amount of air pollution.

Panel to firms: Prove that 324 combination drugs are safe to use

The medicines, known as fixed dose combinations, were declared ‘irrational’ by a Health Ministry panel set up in 2014.

US ends India’s benefits under select trade list

Will uphold national interest, offered resolution, US did not accept: Government

Road ahead for the Commerce ministry: Boosting exports, resolving trade issues key focus areas

India has been facing ‘enormous’ pressure from the Trump administration, which had raised tariffs on steel and aluminum imports from the country last year.

US takes India off currency watchlist

Over the last two years, US put pressure on India by increasing tariffs on products like steel and aluminium,as well as removing the country from its Generalized System of Preferences, which allowed Indian businesses certain trade benefits.

Decline in Foreign Direct Investment inflow: Stressed telecom, uncertainty in pharma to blame

While FDI in telecom sector fell during 2018-19 to $2.67 bn from $6.21 bn a year ago, inflows in pharma dropped to $266 mn in 2018-19 from $1 bn in 2017-18.

100-day agenda: Cheaper medicines, e-pharmacy norms likely to be in focus

A proposal to allow patients to seek compensation for faulty medical devices, a scrutinised industry following government and media investigations into the adverse impacts of certain hip implants by J&J, is also yet to fructify.

‘Uttar Pradesh, Jharkhand, Maharashtra discoms still to recover nearly Rs 67,000 crore’

As per the latest tariff orders until FY18-FY19, the total amount of these funds, known as regulatory assets, outstanding amounted to Rs 76,963 crore.

Why appeals are stuck at WTO, how India will be hit if process breaks down

Over 20 developing countries met in New Delhi last week to discuss ways to prevent the WTO’s dispute resolution system from collapsing due to the logjam in these appointments.

After US FDA, CDSCO issues device alert on 3 Medtronic pacemakers

The Central Drugs Standard Control Organisation (CDSCO) alert on Saturday comes over a week after the US Food and Drug Administration (US FDA) flagged five such models of Medtronic’s pacemakers and cardiac resynchronisation therapy pacemakers (CRT-P) for issues related to their batteries.

Need a new brand name if composition of drug is changed: Pharma regulator

According to a notification issued on Thursday by the CDSCO, the practice of changing the key therapeutic ingredients in a drug formulation without changing the brand name “is not only misleading but may also result in undesirable pharmacological effects as the consumer would take the formulation assuming that it has the earlier composition.”

Patient groups urge HealthMin to ‘discontinue’ J&J TB drug donations

J&J, earlier this month, announced that it would be providing 10,000 courses of bedaquiline, used to treat multi drug-resistant TB, “free of charge” to India through USAID in addition to the 10,000 courses it had committed before.

US FDA finds quality, data issues at Dadra plant of Sun Pharma

Sun Pharma got Form 483 which is issued when investigators observe conditions they deem to be violations of US drug regulations.

The refrain in country’s knitwear hub: Few jobs, rising living costs, GST

The shortage of workers in the region, has left leaving medium and larger garment manufacturers dependent on migrant labourers.

Malvinder and Shivinder Singh and the ‘missing’ funds of a billion-dollar empire

The Indian Express reviews various allegations raised over the last year of diversion of funds previously held by the ex-promoters of Fortis and Ranbaxy.

Daiichi Sankyo Case: Supreme Court reserves order on contempt case against Singh brothers

The court had last week warned the brothers that they could be sent to jail if it was found that they had disobeyed its orders.